98%
921
2 minutes
20
Background: The recent spread of artemisinin (ART)-resistant Plasmodium falciparum represents an emerging global threat to public health. In Southeast Asia, the C580Y mutation of kelch13 (k13) is the dominant mutation of ART-resistant P. falciparum. Therefore, a simple method for the detection of C580Y mutation is urgently needed to enable widespread routine surveillance in the field. The aim of this study is to develop a new diagnostic procedure for the C580Y mutation using loop-mediated isothermal amplification (LAMP) combined with the MinION nanopore sequencer.
Results: A LAMP assay for the k13 gene of P. falciparum to detect the C580Y mutation was successfully developed. The detection limit of this procedure was 10 copies of the reference plasmid harboring the k13 gene within 60 min. Thereafter, amplicon sequencing of the LAMP products using the MinION nanopore sequencer was performed to clarify the nucleotide sequences of the gene. The C580Y mutation was identified based on the sequence data collected from MinION reads 30 min after the start of sequencing. Further, clinical evaluation of the LAMP assay in 34 human blood samples collected from patients with P. falciparum malaria in Indonesia revealed a positive detection rate of 100%. All LAMP amplicons of up to 12 specimens were simultaneously sequenced using MinION. The results of sequencing were consistent with those of the conventional PCR and Sanger sequencing protocol. All procedures from DNA extraction to variant calling were completed within 3 h. The C580Y mutation was not found among these 34 P. falciparum isolates in Indonesia.
Conclusions: An innovative method combining LAMP and MinION will enable simple, rapid, and high-sensitivity detection of the C580Y mutation of P. falciparum, even in resource-limited situations in developing countries.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975513 | PMC |
http://dx.doi.org/10.1186/s12936-018-2362-x | DOI Listing |
medRxiv
June 2025
Department of Pathology and Laboratory Medicine, Brown University, Providence, RI, USA.
The rise of antimalarial drug-resistant poses a major threat to malaria treatment, control, and elimination efforts. Mutations in the () gene confer artemisinin partial resistance (ART-R), compromising the efficacy of combination therapies. In the Horn of Africa, the validated mutation R622I has rapidly emerged in parallel with other mutations elsewhere in Eastern Africa.
View Article and Find Full Text PDFChina CDC Wkly
June 2025
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, NHC Key Laboratory of Parasite and Vector Biology, World Health Organization Collaborating Centre for Tropical Diseases, National Center for International Research on Tropical Diseases; National Institute of Par
What Is Already Known About This Topic?: Artemisinin-based combination therapies (ACTs) remain the first-line treatment for uncomplicated malaria caused by , while chloroquine (CQ) serves as the primary treatment for . However, the global spread of antimalarial drug resistance has become an increasing concern over time.
What Is Added By This Report?: The integrated drug efficacy studies (iDES) demonstrated that artesunate (AS) plus dihydroartemisinin-piperaquine (DHA-PPQ) and chloroquine (CQ) remain effective first-line treatments for and malaria, respectively.
Parasites Hosts Dis
May 2025
Department of Medical Laboratory Science, Babcock University, Illishan 121103, Nigeria.
The continuous Plasmodium falciparum kelch13 (PfK13) genetic alterations conferring resistance to artemisinin-based combination therapies and partner drugs pose a significant threat to effective treatment and control of P. falciparum infection in developing countries. This review evaluates the emergence and epidemiology of the PfK13 mutation associated with artemisinin resistance in the sub-Saharan Africa (SSA) population.
View Article and Find Full Text PDFMalar J
May 2025
Malaria Molecular Epidemiology Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.
Background: The recent emergence of artemisinin resistance in Africa is drawing scrutiny toward the use of alternative anti-malarial therapy based on Artemisia annua and Artemisia afra phytotherapies. This study aimed to determine if either A. annua and A.
View Article and Find Full Text PDFTrop Med Health
April 2025
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.
Background: Nigeria accounts for the greatest burden of malaria disease globally. Malaria control requires an effective treatment after diagnosis. The efficacy of antimalarial drugs can be assessed through the analysis of genetic changes associated with reduced drug sensitivity.
View Article and Find Full Text PDF